SCHEMBL26664432

SCHEMBL26664432

CC(C)(C)OC(=O)N1CCC(c2nc3c(F)cc(Br)cn3n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.45
KDM4E B2RXH2 3/20 0.43
MAPT P10636 3/20 0.43
THRB P10828 1/20 0.43
DPP4 P27487 1/20 0.43
TRPV3 Q8NET8 2/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CRHBP P24387 1/20 0.42
HTT P42858 1/20 0.42
CRHR2 Q13324 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
JAK2 O60674 2/20 0.41
JAK3 P52333 2/20 0.41
PTK2 Q05397 2/20 0.41
GPR119 Q8TDV5 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30672535 0.84 USP30 (0.43) DPP4GPR119USP30
SCHEMBL26664252 0.80 TRPV3 (0.47) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL26664496 0.80 TP53 (0.45) NAMPTKDM4EMAPTTRPV3ALDH1A1
SCHEMBL26664280 0.78 MAPT (0.42) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL25939333 0.77 THRB (0.53) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL26930284 0.76 GPR119 (0.56) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL21979976 0.76 SMN1; SMN2 (0.44) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL23290764 0.73 MAPT (0.43) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL14157519 0.73 SMN1; SMN2 (0.47) KDM4EMAPTTHRBDPP4TRPV3
SCHEMBL15878455 0.73 THRB (0.46) NAMPTKDM4EMAPTTHRBTRPV3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
WO-2025111409-A1 HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING BIOGEN MA INC. (US) 2025-05-30 WO disclosed
EP-4526292-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE Biogen MA Inc. (US) 2025-03-26 EP disclosed
WO-2023225244-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE BIOGEN MA INC. (US) 2023-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 NAMPT 866/4885KDM4E 2060/4885MAPT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.